PL1868614T3 - Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem - Google Patents

Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Info

Publication number
PL1868614T3
PL1868614T3 PL06748657T PL06748657T PL1868614T3 PL 1868614 T3 PL1868614 T3 PL 1868614T3 PL 06748657 T PL06748657 T PL 06748657T PL 06748657 T PL06748657 T PL 06748657T PL 1868614 T3 PL1868614 T3 PL 1868614T3
Authority
PL
Poland
Prior art keywords
progesterone
treatment
brain injury
dosage regimen
traumatic brain
Prior art date
Application number
PL06748657T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PL1868614T3 publication Critical patent/PL1868614T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL06748657T 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem PL1868614T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
PCT/US2006/010797 WO2006102596A2 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
PL1868614T3 true PL1868614T3 (pl) 2013-01-31

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Country Status (15)

Country Link
US (4) US20090325920A1 (pl)
EP (5) EP2030622B1 (pl)
JP (5) JP5295755B2 (pl)
AT (2) ATE499104T1 (pl)
AU (2) AU2006226811B2 (pl)
CA (2) CA2602950C (pl)
CY (2) CY1111478T1 (pl)
DE (1) DE602006020353D1 (pl)
DK (2) DK1868614T3 (pl)
ES (2) ES2392454T3 (pl)
HR (2) HRP20120688T1 (pl)
PL (2) PL1868614T3 (pl)
PT (2) PT2030622E (pl)
RS (1) RS52471B (pl)
WO (2) WO2006102596A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK1868614T3 (da) 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
EP2260052A4 (en) 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
RU2366466C1 (ru) * 2008-03-25 2009-09-10 Олег Васильевич Онысько Способ лечения черепно-мозговой травмы
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
WO2011097571A2 (en) 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CN108283712A (zh) * 2011-04-27 2018-07-17 西北大学 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
IL298436B2 (en) * 2012-01-23 2024-07-01 Sage Therapeutics Inc Pharmaceutical compositions comprising allopregnanolone
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
EP2819649B1 (en) 2012-02-29 2018-01-10 B. Braun Melsungen AG Hormone containing emulsion
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
BR122021022560B1 (pt) * 2012-08-21 2022-08-09 Sage Therapeutics, Inc Kit, método de preparação de dosagens e método de ajuste da quantidade de diluentes e ou alopregnanolona em dispositivo de liberação
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
EP2951184A1 (en) 2013-01-29 2015-12-09 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PT3514158T (pt) 2013-01-29 2023-01-13 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EA201892657A1 (ru) 2016-05-19 2019-05-31 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017306136B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112020015710A2 (pt) 2018-01-31 2020-12-08 Aptinyx Inc. Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
US20220120766A1 (en) * 2019-01-31 2022-04-21 Universite De Geneve Prospective markers in traumatic brain injury (tbi)
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
US20230293722A1 (en) * 2022-01-05 2023-09-21 Metaqor Llc Compositions and Methods for Treating Neurological-associated Disorders
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0382790A4 (en) 1987-08-25 1991-03-27 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
ES2227523T3 (es) * 1993-01-19 2005-04-01 Endorecherche Inc. Usos terapeuticos y sistemas de suministro de deshidroepiandrosterona.
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US6077947A (en) * 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
ES2235187T3 (es) * 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
IL127189A0 (en) 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
EP0981349B1 (en) 1997-05-02 2002-11-06 Wyeth 5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumours and cns diseases
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK1868614T3 (da) * 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron

Also Published As

Publication number Publication date
US20090221544A1 (en) 2009-09-03
WO2006102596A3 (en) 2007-01-18
DK2030622T3 (da) 2011-05-02
CA2602950C (en) 2012-10-30
EP2030622B1 (en) 2011-02-23
US8614203B2 (en) 2013-12-24
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
JP5496407B2 (ja) 2014-05-21
PT1868614E (pt) 2012-11-23
CY1111478T1 (el) 2015-08-05
WO2006102644A9 (en) 2006-11-23
EP1868614A2 (en) 2007-12-26
US20090325920A1 (en) 2009-12-31
EP2431042B1 (en) 2013-06-26
CA2601715A1 (en) 2006-09-28
AU2006226811A1 (en) 2006-09-28
EP2030622A1 (en) 2009-03-04
HRP20120688T1 (hr) 2012-09-30
ES2392454T3 (es) 2012-12-10
HRP20110198T1 (hr) 2011-04-30
JP5295755B2 (ja) 2013-09-18
WO2006102596A2 (en) 2006-09-28
PL2030622T3 (pl) 2011-07-29
HK1128242A1 (en) 2009-10-23
AU2006226774B2 (en) 2010-12-02
US20120245133A1 (en) 2012-09-27
EP1868614B1 (en) 2012-08-08
JP5394059B2 (ja) 2014-01-22
WO2006102644A3 (en) 2007-03-01
JP2011225629A (ja) 2011-11-10
DK1868614T3 (da) 2012-11-12
US20120289491A1 (en) 2012-11-15
WO2006102644A2 (en) 2006-09-28
AU2006226774A1 (en) 2006-09-28
CY1113253T1 (el) 2016-04-13
CA2602950A1 (en) 2006-09-28
HK1112581A1 (en) 2008-09-12
JP2008534512A (ja) 2008-08-28
EP1871382A2 (en) 2008-01-02
AU2006226811B2 (en) 2010-11-25
DE602006020353D1 (de) 2011-04-07
JP2008534515A (ja) 2008-08-28
ATE499104T1 (de) 2011-03-15
RS52471B (sr) 2013-02-28
EP1871382B1 (en) 2011-08-17
JP2014055183A (ja) 2014-03-27
ATE520404T1 (de) 2011-09-15
EP2431042A1 (en) 2012-03-21
JP2013234191A (ja) 2013-11-21
HK1112579A1 (en) 2008-09-12
PT2030622E (pt) 2011-06-02
EP2494976A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
PL1868614T3 (pl) Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2008033792A3 (en) Repetitive transcranial magnetic stimulation for movement disorders
WO2016025635A3 (en) Combination therapy for treating cancer
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CA2875824C (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
FI3370760T3 (fi) Plasminogeenivajauksen plasminogeenikorvaushoito
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
ZA201806684B (en) Methods of treating pediatric cancers
WO2016043874A3 (en) Combination therapy for treating cancer
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2018060528A3 (en) Therapeutic protein
PL1704860T3 (pl) Pochodne benzamidyny do leczenia i zapobiegania zapaleniu śluzówki
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students